Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1551 to 1596 of 1596 results for nice quality standards or clinical guidelines

  1. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough.

  2. Bipolar, schizophrenia and other psychoses: cervical screening (IND85)

    This indicator covers the percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM20

  3. Weight management before, during and after pregnancy (PH27)

    This guideline covers how to assess and monitor body weight and how to prevent someone from becoming overweight or obese before, during and after pregnancy. The aim is to help all women who have a baby to achieve and maintain a healthy weight by adopting a balanced diet and being physically active.

  4. Cardiovascular disease prevention (PH25)

    This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.

  5. Improving outcomes for people with skin tumours including melanoma (CSG8)

    This guideline covers how healthcare services for people with skin cancers should be organised. It aims to improve diagnosis and care by recommending which healthcare professionals should be involved and at which stage.

  6. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

  7. Depression in adults with a chronic physical health problem: recognition and management (CG91)

    This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.

  8. Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

    Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.

  9. Rehabilitation after critical illness in adults (CG83)

    This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.

  10. Physical activity for children and young people (PH17)

    This guideline covers promoting physical activity for children and young people aged under 18 at home, preschool, school and in the community. It includes raising awareness of the benefits of physical activity, listening to what children and young people want, planning and providing spaces and facilities, and helping families build physical activity into their daily lives.

  11. Borderline personality disorder: recognition and management (CG78)

    This guideline covers recognising and managing borderline personality disorder. It aims to help people with borderline personality disorder to manage feelings of distress, anxiety, worthlessness and anger, and to maintain stable and close relationships with others.

  12. Mental wellbeing in over 65s: occupational therapy and physical activity interventions (PH16)

    This guideline covers promoting mental wellbeing in people aged over 65. It focuses on practical support for everyday activities, based on occupational therapy principles and methods. This includes working with older people and their carers to agree what kind of support they need.

  13. Cardiovascular disease: identifying and supporting people most at risk of dying early (PH15)

    This guideline covers the risk of early death from heart disease and other smoking-related illnesses. It aims to reduce the number of people who are disadvantaged dying prematurely by ensuring people have better access to flexible, well-coordinated treatment and support.

  14. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

  15. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in adults and children aged 12 and over.

  16. Behaviour change: general approaches (PH6)

    This guideline covers a set of principles that can be used to help people change their behaviour. The aim is for practitioners to use these principles to encourage people to adopt a healthier lifestyle by, for example, stopping smoking, adopting a healthy diet and being more physically active.

  17. Drug misuse in over 16s: psychosocial interventions (CG51)

    This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

  18. Drug misuse in over 16s: opioid detoxification (CG52)

    This guideline covers helping adults and young people over 16 who are dependent on opioids to stop using drugs. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

  19. Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)

    Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.

  20. Faecal incontinence in adults: management (CG49)

    This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis. It aims to improve the physical and mental health and quality of life of people with faecal incontinence.

  21. Etanercept and efalizumab for the treatment of adults with psoriasis (TA103)

    Evidence-based recommendations on etanercept (Enbrel) for treating severe psoriasis in adults.

  22. Improving outcomes for people with brain and other central nervous system tumours (CSG10)

    This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  23. Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31)

    This guideline covers recognising, assessing, diagnosing and treating obsessive-compulsive disorder and body dysmorphic disorder in adults, young people and children (aged 8 years and older). It aims to improve the diagnosis and treatment of obsessive-compulsive disorder and body dysmorphic disorder. It includes recommendations on how families and carers may be able to support people with either of these conditions, and how they can get support for themselves.

  24. Low dose rate brachytherapy for localised prostate cancer (IPG132)

    Evidence-based recommendations on low dose rate brachytherapy for localised prostate cancer. This involves placing small radioactive seeds into the prostate that give off low doses of radiation to destroy cancer cells.

  25. Cryotherapy for recurrent prostate cancer (IPG119)

    Evidence-based recommendations on cryotherapy for treating recurrent prostate cancer. This involves putting special needles or probes into the prostate and using Argon gas to freeze and destroy the cancerous prostate tissue.

  26. High-intensity focused ultrasound for prostate cancer (IPG118)

    Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.

  27. Lung volume reduction surgery for advanced emphysema (IPG114)

    Evidence-based recommendations on lung volume reduction surgery for treating advanced emphysema. This involves removing damaged lung tissue using a special stapling device, a laser, or both.

  28. Dental checks: intervals between oral health reviews (CG19)

    This guideline covers assigning recall intervals between oral health reviews that are appropriate to the needs of individual patients. The guideline takes account of the effect of dental checks on: people’s wellbeing, general health and preventive habits; caries incidence and avoiding restorations; periodontal health and avoiding tooth loss; and avoiding pain and anxiety. It aims to improve or maintain patients’ quality of life and reduce morbidity associated with oral and dental disease.

  29. Sacral nerve stimulation for urge incontinence and urgency-frequency (IPG64)

    Evidence-based recommendations on sacral nerve stimulation for urge incontinence and urgency-frequency. This involves placing electrodes and connecting them to an implantable pulse generator.

  30. Holmium laser prostatectomy (IPG17)

    Evidence-based recommendations on holmium laser prostatectomy. This involves using heat from a laser to break down the extra tissue in the prostate.

  31. Laparoscopic laser myomectomy (IPG23)

    Evidence-based recommendations on laparoscopic laser myomectomy. This involves passing a fine telescope (laparascope) through small cuts in the abdomen and uterus wall, and using a laser to destroy the fibroids.

  32. Cardiometabolic disease prevention and treatment guidelines

    This webpage covers all NICE's guidelines on cardiometabolic disease prevention and treatment The table presents the...

  33. Abdominal aortic aneurysm

    Awaiting development [GID-QS10035] Expected publication date: TBC

  34. Idebenone for treating Duchenne muscular dystrophy [ID1092]

    Discontinued [GID-TA10310]

  35. Juvenile idiopathic arthritis - abatacept [ID27]

    Discontinued [GID-TAG402]

  36. Indoor air quality at home

    In development [GID-QS10113] Expected publication date: TBC

  37. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development [GID-TA10555] Expected publication date: TBC

  38. Perioperative care

    Awaiting development [GID-QS10094] Expected publication date: TBC

  39. Antimicrobial stewardship

    All NICE products on antimicrobial stewardship. Includes any guidance, advice and quality standards.

  40. NICE glossary

    The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.

  41. Anhydrous sodium thiosulfate (Pedmarqsi) for preventing ototoxicity caused by cisplatin chemotherapy in people aged 1 month to 17 years with localised solid tumours [ID1001]

    In development [GID-TA10611] Expected publication date: TBC

  42. Kidney Cancer

    In development [GID-QS10186] Expected publication date: TBC

  43. Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]

    In development [GID-TA11408] Expected publication date: TBC

  44. Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]

    In development [GID-TA10877] Expected publication date: 20 November 2024

  45. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.